MA33533B1 - Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles - Google Patents

Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles

Info

Publication number
MA33533B1
MA33533B1 MA34640A MA34640A MA33533B1 MA 33533 B1 MA33533 B1 MA 33533B1 MA 34640 A MA34640 A MA 34640A MA 34640 A MA34640 A MA 34640A MA 33533 B1 MA33533 B1 MA 33533B1
Authority
MA
Morocco
Prior art keywords
disorders
diseases
treatment
proliferative
cancer
Prior art date
Application number
MA34640A
Other languages
Arabic (ar)
English (en)
Inventor
Vijayalakshmi Ramanan
Irene Sophie Tobias
Dauntel Specht Verwijs
Raymond D Skwierczynski
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42697590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33533(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA33533B1 publication Critical patent/MA33533B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques inédites contenant le composé de formule (I) : (formule I), ou un sel pharmaceutiquement acceptable de celui-ci, et pouvant être utilisées pour la production en série d'une forme galénique destinée à la voie orale. L'invention concerne également des procédés de production de ladite forme galénique destinée à la voie orale et l'utilisation de ladite composition pharmaceutique dans le cadre du traitement de patients souffrant de maladies, de troubles ou d'affections impliquant la survie, la prolifération et la migration cellulaires, dont les affections prolifératives inflammatoires chroniques, les affections oculaires prolifératives, les troubles prolifératifs bénins et les cancers ou, encore, dans le cadre du traitement de patients sujets à de tels troubles, maladies ou affections.
MA34640A 2009-07-31 2012-02-16 Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles MA33533B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23021209P 2009-07-31 2009-07-31
PCT/US2010/002109 WO2011014248A1 (fr) 2009-07-31 2010-07-28 Compositions pharmaceutiques utilisables dans le cadre du traitement du cancer et d'autres maladies ou affections

Publications (1)

Publication Number Publication Date
MA33533B1 true MA33533B1 (fr) 2012-08-01

Family

ID=42697590

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34640A MA33533B1 (fr) 2009-07-31 2012-02-16 Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles

Country Status (30)

Country Link
US (3) US20110039826A1 (fr)
EP (1) EP2459173B1 (fr)
JP (2) JP2013500965A (fr)
KR (1) KR101762285B1 (fr)
CN (2) CN103893186B (fr)
AR (1) AR077436A1 (fr)
AU (1) AU2010276741B2 (fr)
BR (1) BR112012002265B8 (fr)
CA (1) CA2769531C (fr)
CL (1) CL2012000261A1 (fr)
CO (1) CO6612185A2 (fr)
CR (1) CR20120084A (fr)
EA (1) EA025277B1 (fr)
EC (1) ECSP12011703A (fr)
GE (1) GEP201606513B (fr)
IL (1) IL217839A (fr)
IN (1) IN2012DN01237A (fr)
JO (1) JO3434B1 (fr)
MA (1) MA33533B1 (fr)
MX (2) MX2012001196A (fr)
MY (1) MY174084A (fr)
NZ (1) NZ598096A (fr)
PE (1) PE20120788A1 (fr)
SG (2) SG10201404483VA (fr)
TN (1) TN2012000046A1 (fr)
TW (1) TWI522357B (fr)
UA (1) UA110463C2 (fr)
UY (1) UY32822A (fr)
WO (1) WO2011014248A1 (fr)
ZA (1) ZA201200944B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50568B8 (sr) * 2004-05-14 2019-08-30 Millennium Pharm Inc Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze
MX2011006725A (es) * 2008-12-22 2011-09-15 Millennium Pharm Inc Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
TWI392514B (zh) * 2010-01-29 2013-04-11 Colgate Palmolive Co 具有高微生物效力之不含氟化物及陰離子表面活性劑的潔牙劑
CN102770024A (zh) 2010-02-19 2012-11-07 米伦纽姆医药公司 4-{[9-氯-7-(2-氟-6-甲氧基苯基)-5h-嘧啶并[5,4-d][2]苯并氮杂卓-2基]氨基}-2-甲氧基苯甲酸钠的结晶形式
AR086656A1 (es) 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
WO2014153509A1 (fr) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combinaison d'inhibiteurs catalytiques de mtorc1/2 et inhibiteurs sélectifs de la kinase aurora a
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼインヒビターと化学療法剤の投与
USD797120S1 (en) 2015-08-28 2017-09-12 Samsung Electronics Co., Ltd. Display screen or portion thereof with graphical user interface
WO2025075211A1 (fr) 2023-10-03 2025-04-10 Takeda Pharmaceutical Company Limited Alisertib et paclitaxel pour le traitement du cancer du poumon à petites cellules
WO2025245045A1 (fr) 2024-05-21 2025-11-27 The Regents Of The University Of California Méthodes de traitement du cancer du poumon

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747487A (en) * 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
WO1998028281A1 (fr) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Derives polycyclique fondus de 2-aminopyrimidine, leur preparation et leur utilisation comme inhibiteurs de proteine tyrosine-kinase
CN101259270A (zh) 1999-08-11 2008-09-10 拜奥根Idec公司 用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者
WO2001072299A1 (fr) * 2000-03-24 2001-10-04 Baker Norton Pharmaceuticals, Inc. Compositions a base de taxane et procedes d'utilisation
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
RS50568B8 (sr) * 2004-05-14 2019-08-30 Millennium Pharm Inc Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze
US20070104785A1 (en) * 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
MX2008008320A (es) * 2005-12-23 2008-09-03 Smithkline Beecham Corp Inhibidores de azaindol de aurora cinasas.
EP2037919A2 (fr) 2006-06-30 2009-03-25 Schering Corporation Procédé d'utilisation de pipéridines substituées qui augmentent l'activité de p53
DE602007005139D1 (de) * 2006-07-21 2010-04-15 Novartis Ag Formulierungen für benzimidazolylpyridylether
US7718648B2 (en) * 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US20090203671A1 (en) * 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
MX2011006725A (es) * 2008-12-22 2011-09-15 Millennium Pharm Inc Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CN102770024A (zh) * 2010-02-19 2012-11-07 米伦纽姆医药公司 4-{[9-氯-7-(2-氟-6-甲氧基苯基)-5h-嘧啶并[5,4-d][2]苯并氮杂卓-2基]氨基}-2-甲氧基苯甲酸钠的结晶形式

Also Published As

Publication number Publication date
CN102548539A (zh) 2012-07-04
JP2013500965A (ja) 2013-01-10
BR112012002265B8 (pt) 2021-05-25
CO6612185A2 (es) 2013-02-01
WO2011014248A1 (fr) 2011-02-03
BR112012002265B1 (pt) 2021-01-12
CR20120084A (es) 2012-06-01
TW201107331A (en) 2011-03-01
CN103893186A (zh) 2014-07-02
BR112012002265A2 (pt) 2016-06-14
MY174084A (en) 2020-03-09
US20110039826A1 (en) 2011-02-17
AU2010276741B2 (en) 2016-07-14
EP2459173B1 (fr) 2018-02-28
KR101762285B1 (ko) 2017-07-28
GEP201606513B (en) 2016-07-25
UY32822A (es) 2011-01-31
AR077436A1 (es) 2011-08-24
ECSP12011703A (es) 2012-03-30
TN2012000046A1 (en) 2013-09-19
JP2015091877A (ja) 2015-05-14
KR20120053008A (ko) 2012-05-24
CA2769531C (fr) 2017-11-07
EP2459173A1 (fr) 2012-06-06
EA201270205A1 (ru) 2012-07-30
ZA201200944B (en) 2015-07-29
JP6014695B2 (ja) 2016-10-25
US20140073630A1 (en) 2014-03-13
US9504693B2 (en) 2016-11-29
SG177751A1 (en) 2012-02-28
IL217839A (en) 2017-01-31
MX2012001196A (es) 2012-03-14
PE20120788A1 (es) 2012-07-22
CN103893186B (zh) 2019-07-09
UA110463C2 (ru) 2016-01-12
JO3434B1 (ar) 2019-10-20
CL2012000261A1 (es) 2012-08-03
NZ598096A (en) 2014-05-30
AU2010276741A1 (en) 2012-03-01
IN2012DN01237A (fr) 2015-05-15
IL217839A0 (en) 2012-03-29
US9127011B2 (en) 2015-09-08
CA2769531A1 (fr) 2011-02-03
EA025277B1 (ru) 2016-12-30
TWI522357B (zh) 2016-02-21
SG10201404483VA (en) 2014-10-30
MX348197B (es) 2017-06-05
US20160158244A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
JP6595565B2 (ja) 免疫関連及び炎症性疾患の治療
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA38138A1 (fr) Dérivés inédits de quinolone
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA31311B1 (fr) Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p)
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA29791B1 (fr) Composes therapeutiques.
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
MA34308B1 (fr) Triazolopyridines substituées
MA32798B1 (fr) Acides naphtylacétiques
MA34158B1 (fr) Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée
MA33463B1 (fr) Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique
MA35932B1 (fr) Pyrazolopyrimidinyle inhibiteurs de l'enzyme d'activation de l'ubiquitine
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine